CIK 0001069899 · Large accelerated filer
PHIBRO ANIMAL HEALTH CORP
Sign in to watch- Ticker
- PAHC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 131840497
- Phone
- 201-329-7300
- Business address
- GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., SUITE 21, TEANECK, NJ, 07666
- Former names
- PHILIPP BROTHERS CHEMICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-11 | David Glenn Chief Financial Officer | Other disposition | −12,528 | $51.63 | $647K | 52,317 |
| 2026-02-10 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −50,994 | $51.76 | $2.6M | 71,964 |
| 2026-02-10 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −7,020 | $52.17 | $366K | 64,944 |
| 2026-02-09 | David Glenn Chief Financial Officer | Option exercise | +30,000 | 64,845 | ||
| 2026-02-09 | David Glenn Chief Financial Officer | Option exercise · Restricted Stock Units | −30,000 | 240,000 | ||
| 2026-02-05 | BENDHEIM JACK President and CEO | Conversion 10b5-1 | +185,000 | 233,800 | ||
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −409 | $44.47 | $18K | 233,391 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −3,640 | $45.42 | $165K | 229,751 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −3,171 | $46.68 | $148K | 226,580 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −38,209 | $47.91 | $1.8M | 188,371 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −46,275 | $48.65 | $2.3M | 142,096 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −19,138 | $49.57 | $949K | 122,958 |
| 2026-02-05 | BENDHEIM JACK President and CEO | Conversion · Class B Common Stock 10b5-1 | −185,000 | 19,696,034 | ||
| 2026-02-04 | BENDHEIM JACK President and CEO | Conversion 10b5-1 | +30,000 | 52,320 | ||
| 2026-02-04 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −3,520 | $41.15 | $145K | 48,800 |
| 2026-02-04 | BENDHEIM JACK President and CEO | Conversion · Class B Common Stock 10b5-1 | −30,000 | 19,881,034 | ||
| 2026-02-03 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −6,689 | $41.25 | $276K | 25,291 |
| 2026-02-03 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −2,971 | $41.97 | $125K | 22,320 |
| 2026-01-30 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −6,693 | $40.09 | $268K | 31,980 |
| 2026-01-29 | BENDHEIM JACK President and CEO | Sale 10b5-1 | −6,772 | $40.12 | $272K | 38,673 |
Page 5 of 18 · 343 trades